The objective of this survey was to determine the level of experience OB/GYN (Obstetrics & Gynecology) physicians in the state of Arkansas have in seeing and managing patients with vulvar pain, commonly known as vulvodynia. The 8 question, anonymous survey was mailed to Arkansas OB/GYN physicians. The survey assessed the experience of the providers, the age range of their patients, and whether or not they treat and/or refer. Thirty of 182 surveys were returned for a rate of 16.4%. The survey revealed that physicians are moderately comfortable treating vulvodynia within their practice and refer mostly for treatment failure.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Vulvodynia Primary Care Toolkit: results of a mixed-method evaluation with community-based family physicians in British Columbia.
Fam Pract
January 2025
Department of Obstetrics and Gynaecology, 2775 Laurel Street, University of British Columbia, Vancouver, British Columbia, V5Z 1M9, Canada.
Background: Healthcare providers often lack awareness, knowledge, and confidence in managing vulvodynia, which can lead to difficulties with diagnosis and treatment for individuals with the condition.
Objective: To develop and test an educational online toolkit tailored to supporting community-based primary care providers with diagnosis, treatment, and patient support for vulvodynia.
Methods: A sample of 19 community-based family physicians completed online surveys before and after testing the Vulvodynia Primary Care Toolkit (the toolkit hereafter) in their practice for 6 months.
Treatment of Genitourinary Syndrome of Menopause in Breast Cancer and Gynecologic Cancer Survivors: Retrospective Analysis of Efficacy and Safety of Vaginal Estriol, Vaginal Dehydroepiandrosterone and Ospemifene.
J Menopausal Med
December 2024
Department of Obstetrics and Gynaecology, Sandro Pertini Hospital, Roma, Italy.
Objectives: To compare the efficacy and safety of three different treatment options (vaginal estriol, vaginal dehydroepiandrosterone (DHEA), and ospemifene) for treating genitourinary syndrome of menopause (GSM) in breast cancer and gynecologic cancer survivors.
Methods: A retrospective comparative analysis was performed among 185 cancer survivors (including breast, endometrial, ovarian, cervical, and vulvar cancer) affected by GSM. Women were divided into three groups according to the prescribed therapy (vaginal estriol, vaginal DHEA, and ospemifene).
Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study.
Clin Breast Cancer
December 2024
Sermonix Pharmaceuticals, Columbus, OH.
Background: Lasofoxifene, a novel endocrine therapy (ET), showed antitumor activity versus fulvestrant in women with ESR1-mutated, metastatic breast cancer (mBC) that progressed on prior ET (phase 2, ELAINE 1 study). We investigated changes in genitourinary syndrome of menopause (GSM) vulvar-vaginal symptoms with lasofoxifene and how patient/disease characteristics affect baseline vulvar-vaginal symptoms in ELAINE 1.
Methods: Women were randomized to oral lasofoxifene 5 mg/day or IM fulvestrant 500 mg (days 1, 15, and 29, then every 28 days) until disease progression/severe toxicity.
GUT, VAGINAL AND URINARY MICROBIOTA AS POTENTIAL BIOMARKERS OF SENSITIZATION IN WOMEN WITH CHRONIC PELVIC PAIN.
Am J Obstet Gynecol
January 2025
Nantes University, Inserm, TENS, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, France.
Background: A subgroup of patients with chronic pelvic pain (CPP) exhibit organ sensitization, whose origin and mechanism remains largely unknown. Changes in microbiota composition in pelvic organs have been found to be associated with various pelvic pathological conditions. Therefore, a comprehensive analysis of the gut and genito-urinary microbiota composition and interactions in women with CPP may be key to understanding their involvement in the sensitization processes.
View Article and Find Full Text PDFAcquired Vulvar Lymphangioma Following CO Laser Treatment for Sebaceous Gland Nevus in a 10-Year-Old Girl: A Case Report.
Clin Cosmet Investig Dermatol
January 2025
Guangzhou Dermatology Hospital, Guangzhou, Guangdong, 510095, People's Republic of China.
Acquired vulvar lymphangioma (AVL) is a rare condition characterized by abnormal lymphatic vessels in the vulva. We describe a 10-year-old female patient who presented with vulvar swelling for 23 days. She has no history of sexual assault and irradiation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!